First In Human open-label dose-escalating trial with expansion cohorts to evaluate safety of Axl specific antibody drug conjugate (HuMax -AXL-ADC) in patients with solid tumors

Brief description of study

If you have you have relapsed cancer or cancer not responding to treatment of one of the following types: non-small cell lung cancer (NSCLC), melanoma, sarcoma, solid tumors that have failed treatment with a PD-1/PD-L1 inhibitor, you may qualify for this Phase I study. The main goal of this research study is to determine the maximum tolerated dose (MTD) of an investigational drug, HuMax-AXL-ADC, and see if the drug is safe when given to people with solid tumors.


Clinical Study Identifier: s17-00964
ClinicalTrials.gov Identifier: NCT02988817
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.